Clinical Trial Detail

NCT ID NCT01992653
Title A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

non-Hodgkin lymphoma

diffuse large B-cell lymphoma

lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Prednisone

Rituximab

Polatuzumab vedotin-piiq

Obinutuzumab

Age Groups: senior

No variant requirements are available.